Do analysts prefer PXMD or ADTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PaxMedica 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, PXMD or ADTX?

PaxMedica has higher earnings, but lower revenue than Aditxt. PaxMedica is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PaxMedica N/A N/A -$18.29M -$6.09 N/A Aditxt $14.34K 0.13 -$41.71M -$100.79 thousand N/A

Is PXMD or ADTX more profitable?

PaxMedica has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Aditxt's return on equity of -374.60% beat PaxMedica's return on equity. Company Net Margins Return on Equity Return on Assets PaxMedica N/A -3,167.89% -560.35% Aditxt -360,152.50% -374.60% -105.93%

Do analysts prefer SCPS or ADTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scopus BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, SCPS or ADTX?

Scopus BioPharma has higher earnings, but lower revenue than Aditxt. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scopus BioPharma N/A N/A -$11.61M N/A N/A Aditxt $14.34K 0.13 -$41.71M -$100.79 thousand N/A

Do analysts recommend GNCA or ADTX?

Given Genocea Biosciences' higher possible upside, analysts plainly believe Genocea Biosciences is more favorable than Aditxt. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genocea Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, GNCA or ADTX?

Genocea Biosciences has higher revenue and earnings than Aditxt. Aditxt is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genocea Biosciences $1.91M 0.00 -$33.20M -$0.61 N/A Aditxt $14.34K 0.13 -$41.71M -$100.79 thousand N/A

Is GNCA or ADTX more profitable?

Genocea Biosciences has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Genocea Biosciences' return on equity of -182.88% beat Aditxt's return on equity. Company Net Margins Return on Equity Return on Assets Genocea Biosciences N/A -182.88% -62.76% Aditxt -360,152.50% -374.60% -105.93%

Do analysts prefer ADTX or ARDS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aridis Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate GNCAQ or ADTX?

Given Genocea Biosciences' higher probable upside, analysts clearly believe Genocea Biosciences is more favorable than Aditxt. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genocea Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, GNCAQ or ADTX?

Genocea Biosciences has higher earnings, but lower revenue than Aditxt. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genocea Biosciences N/A N/A N/A N/A N/A Aditxt $14.34K 0.13 -$41.71M -$100.79 thousand N/A

Aditxt (ADTX) Competitors

$0.0023 0.00 (-17.86%)

As of 10/14/2026 03:59 PM Eastern

Compare

ADTX vs. PXMD, SCPS, GNCA, ARDS, and GNCAQ

Should you buy Aditxt stock or one of its competitors? Aditxt's main competitors and comparable companies include PaxMedica (PXMD), Scopus BioPharma (SCPS), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), and Genocea Biosciences (GNCAQ). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Aditxt compare to PaxMedica?

PaxMedica (NASDAQ:PXMD) and Aditxt (NASDAQ:ADTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PaxMedica	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PaxMedica has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Aditxt's return on equity of -374.60% beat PaxMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PaxMedica	N/A	-3,167.89%	-560.35%
Aditxt	-360,152.50%	-374.60%	-105.93%

4.9% of PaxMedica shares are held by institutional investors. Comparatively, 15.5% of Aditxt shares are held by institutional investors. 1.0% of PaxMedica shares are held by insiders. Comparatively, 0.0% of Aditxt shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

PaxMedica has higher earnings, but lower revenue than Aditxt. PaxMedica is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A
Aditxt	$14.34K	0.13	-$41.71M	-$100.79 thousand	N/A

PaxMedica has a beta of -0.99, suggesting that its stock price is 199% less volatile than the broader market. Comparatively, Aditxt has a beta of 1.34, suggesting that its stock price is 34% more volatile than the broader market.

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Aditxt'saverage media sentiment score.

Company	Overall Sentiment
PaxMedica	Neutral
Aditxt	Neutral

Summary

Aditxt beats PaxMedica on 7 of the 11 factors compared between the two stocks.

How does Aditxt compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and Aditxt (NASDAQ:ADTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scopus BioPharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Scopus BioPharma has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Scopus BioPharma's return on equity of 0.00% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scopus BioPharma	N/A	N/A	N/A
Aditxt	-360,152.50%	-374.60%	-105.93%

15.5% of Aditxt shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by insiders. Comparatively, 0.0% of Aditxt shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Scopus BioPharma has higher earnings, but lower revenue than Aditxt.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A
Aditxt	$14.34K	0.13	-$41.71M	-$100.79 thousand	N/A

Scopus BioPharma has a beta of -0.32, suggesting that its stock price is 132% less volatile than the broader market. Comparatively, Aditxt has a beta of 1.34, suggesting that its stock price is 34% more volatile than the broader market.

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Aditxt'saverage media sentiment score.

Company	Overall Sentiment
Scopus BioPharma	Neutral
Aditxt	Neutral

Summary

Scopus BioPharma beats Aditxt on 5 of the 9 factors compared between the two stocks.

How does Aditxt compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCA) and Aditxt (NASDAQ:ADTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Genocea Biosciences has higher revenue and earnings than Aditxt. Aditxt is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genocea Biosciences	$1.91M	0.00	-$33.20M	-$0.61	N/A
Aditxt	$14.34K	0.13	-$41.71M	-$100.79 thousand	N/A

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Aditxt'saverage media sentiment score.

Company	Overall Sentiment
Genocea Biosciences	Neutral
Aditxt	Neutral

Given Genocea Biosciences' higher possible upside, analysts plainly believe Genocea Biosciences is more favorable than Aditxt.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genocea Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Genocea Biosciences has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market. Comparatively, Aditxt has a beta of 1.34, meaning that its stock price is 34% more volatile than the broader market.

Genocea Biosciences has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Genocea Biosciences' return on equity of -182.88% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genocea Biosciences	N/A	-182.88%	-62.76%
Aditxt	-360,152.50%	-374.60%	-105.93%

0.6% of Genocea Biosciences shares are held by institutional investors. Comparatively, 15.5% of Aditxt shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by insiders. Comparatively, 0.0% of Aditxt shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Genocea Biosciences beats Aditxt on 9 of the 12 factors compared between the two stocks.

How does Aditxt compare to Aridis Pharmaceuticals?

Aditxt (NASDAQ:ADTX) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Aridis Pharmaceuticals has lower revenue, but higher earnings than Aditxt. Aridis Pharmaceuticals is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aditxt	$14.34K	0.13	-$41.71M	-$100.79 thousand	N/A
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	-$0.02	N/A

In the previous week, Aditxt's average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Aditxt	Neutral
Aridis Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aridis Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Aditxt has a beta of 1.34, suggesting that its share price is 34% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 47.61, suggesting that its share price is 4,661% more volatile than the broader market.

15.5% of Aditxt shares are held by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 0.0% of Aditxt shares are held by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Aridis Pharmaceuticals has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Aridis Pharmaceuticals' return on equity of 0.00% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aditxt	-360,152.50%	-374.60%	-105.93%
Aridis Pharmaceuticals	N/A	N/A	N/A

Summary

Aridis Pharmaceuticals beats Aditxt on 7 of the 11 factors compared between the two stocks.

How does Aditxt compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCAQ) and Aditxt (NASDAQ:ADTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Genocea Biosciences has higher earnings, but lower revenue than Aditxt.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genocea Biosciences	N/A	N/A	N/A	N/A	N/A
Aditxt	$14.34K	0.13	-$41.71M	-$100.79 thousand	N/A

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Aditxt'saverage media sentiment score.

Company	Overall Sentiment
Genocea Biosciences	Neutral
Aditxt	Neutral

Genocea Biosciences has a beta of 2.44, meaning that its share price is 144% more volatile than the broader market. Comparatively, Aditxt has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market.

Given Genocea Biosciences' higher probable upside, analysts clearly believe Genocea Biosciences is more favorable than Aditxt.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genocea Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

15.5% of Aditxt shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 0.0% of Aditxt shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Genocea Biosciences has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Genocea Biosciences' return on equity of 0.00% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genocea Biosciences	N/A	N/A	N/A
Aditxt	-360,152.50%	-374.60%	-105.93%

Summary

Genocea Biosciences beats Aditxt on 6 of the 10 factors compared between the two stocks.

Get Aditxt News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADTX vs. The Competition

Export

Metric	Aditxt	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2K	$12.13B	$7.18B	$13.18B
Dividend Yield	N/A	2.63%	2.52%	19.60%
P/E Ratio	0.00	641.56	203.79	19.22
Price / Sales	0.13	749.43	557.65	74.70
Price / Cash	N/A	84.08	76.68	52.75
Price / Book	0.00	9.15	10.51	5.92
Net Income	-$41.71M	$2.82B	$3.50B	$380.90M
7 Day Performance	N/A	-3.80%	-3.51%	-3.85%
1 Month Performance	N/A	-7.64%	-7.77%	-6.37%
1 Year Performance	N/A	-6.14%	0.80%	-6.01%

Aditxt Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADTX Aditxt	0.0381 of 5 stars	$0.00 -17.9%	N/A	-100.0%	$2K	$14.34K	N/A	26	Gap Down
PXMD PaxMedica	N/A	$0.00 flat	N/A	+400.0%	$8K	N/A	N/A	6	Gap Up
SCPS Scopus BioPharma	N/A	$0.00 flat	N/A	+33.3%	$7K	N/A	N/A	9
GNCA Genocea Biosciences	N/A	N/A	N/A	N/A	$6K	$1.91M	N/A	70
ARDS Aridis Pharmaceuticals	N/A	$0.00 flat	N/A	-50.0%	$5K	N/A	N/A	37

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADTX) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aditxt (ADTX) Competitors

ADTX vs. PXMD, SCPS, GNCA, ARDS, and GNCAQ

How does Aditxt compare to PaxMedica?

Summary

How does Aditxt compare to Scopus BioPharma?

Summary

How does Aditxt compare to Genocea Biosciences?

Summary

How does Aditxt compare to Aridis Pharmaceuticals?

Summary

How does Aditxt compare to Genocea Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADTX vs. The Competition

Aditxt Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aditxt (ADTX) Competitors

ADTX vs. PXMD, SCPS, GNCA, ARDS, and GNCAQ

How does Aditxt compare to PaxMedica?

Do analysts prefer PXMD or ADTX?

Is PXMD or ADTX more profitable?

Do institutionals and insiders have more ownership in PXMD or ADTX?

Which has better valuation & earnings, PXMD or ADTX?

Which has more risk & volatility, PXMD or ADTX?

Does the media favor PXMD or ADTX?

Summary

How does Aditxt compare to Scopus BioPharma?

Do analysts prefer SCPS or ADTX?

Is SCPS or ADTX more profitable?

Do institutionals and insiders have more ownership in SCPS or ADTX?

Which has better valuation & earnings, SCPS or ADTX?

Which has more risk & volatility, SCPS or ADTX?

Does the media favor SCPS or ADTX?

Summary

How does Aditxt compare to Genocea Biosciences?

Which has stronger earnings and valuation, GNCA or ADTX?

Does the media favor GNCA or ADTX?

Do analysts recommend GNCA or ADTX?

Which has more risk and volatility, GNCA or ADTX?

Is GNCA or ADTX more profitable?

Do institutionals and insiders have more ownership in GNCA or ADTX?

Summary

How does Aditxt compare to Aridis Pharmaceuticals?

Which has better earnings and valuation, ADTX or ARDS?

Does the media prefer ADTX or ARDS?

Do analysts prefer ADTX or ARDS?

Which has more risk and volatility, ADTX or ARDS?

Do insiders and institutionals hold more shares of ADTX or ARDS?

Is ADTX or ARDS more profitable?

Summary

How does Aditxt compare to Genocea Biosciences?

Which has better valuation and earnings, GNCAQ or ADTX?

Does the media favor GNCAQ or ADTX?

Which has more volatility and risk, GNCAQ or ADTX?

Do analysts rate GNCAQ or ADTX?

Do insiders & institutionals hold more shares of GNCAQ or ADTX?

Is GNCAQ or ADTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADTX vs. The Competition

Aditxt Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools